Project Grant R01HL180499
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $756K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded a $1,045,688 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Reneurogen LLC to develop a novel drug candidate for treating vaso-occlusive crisis, pain, and other vascular complications in sickle cell disease. The funding will support research to demonstrate that the drug candidate, N-acetyl-lysyltyrosylcysteine amide (KYC), can inhibit the vicious cycle of hemoglobin polymerization, impaired red blood cell...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
- This $146,013 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) will be used by The Medical College of Wisconsin, Inc. to establish a large patient cohort leveraging electronic health record and administrative claims data to determine the risks of cardiopulmonary and renal end organ complications and factors associated with frequent acute care use among individuals with sickle cell disease. The award period...
- The federal Project Grant award in the amount of $503,870.00 was provided by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) to Drexel University. The award is focused on developing a mechanistic understanding of how fetal hemoglobin (HbF) modulates the polymerization of sickle cell hemoglobin (HbS), which is the root cause of sickle cell disease. The research aims to address critical knowledge gaps that limit the rational optimization of...
- This $573,821 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of endothelin-1 (ET-1) in regulating renal iron handling in sickle cell disease (SCD). The principal investigator at the University of North Carolina at Chapel Hill (UNC-CH) will investigate how ET-1/ETA signaling promotes renal iron accumulation in SCD, which is linked to the development of chronic kidney disease in up to 80% of SCD...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance the understanding of the molecular and neurobiological mechanisms underlying chronic pain in sickle cell disease (SCD) and develop effective pharmacologic treatments. The $1,103,783 award to the University of Illinois will utilize well-characterized sickle cell transgenic mouse models to study epigenetic, neurobiology, and gut microbiota...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides funding of $2,968,063.02 to the Children's Research Institute to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for treating vaso-occlusive crisis in sickle cell disease. The study aims to determine if the administration of citrulline, which plays a role in nitric oxide production, can lead to...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- This federal Project Grant award for $111,626.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage populations and their role in pulmonary hypertension associated with sickle cell disease. The 2-year research project aims to determine if targeting iron release can modify CD169+ macrophages and adaptive immune cells, and if ablation of CD169+ macrophages can inhibit the progression of...
- The federal Project Grant award of $701,890.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The University of Illinois in Chicago is conducting this research, which aims to better understand sunitinib's effects on the endothelial cells that line blood vessels, in order to mitigate the risk of cardiovascular toxicity...